8-K: Marizyme to Restate Prior Financial Statements Due to Accounting Errors

Marizyme, Inc. announced that it will restate its financial statements for the quarterly periods ended March 31, 2024, and June 30, 2024, due to material misstatements related to debt/equity transactions.

Summary

• Marizyme, Inc. will restate its financial statements for the quarters ended March 31, 2024, and June 30, 2024.
• The restatement is due to misstatements related to the technical analysis of debt/equity transactions.
• The company determined that these errors were material and resulted from a material weakness in internal control over financial reporting.
• The errors involve the incorrect recording of differences between the reacquisition price of debt and the net carrying amount of extinguished debt related to convertible notes.
• The company will recognize these differences as a loss in the period of extinguishment.
• The fair market value of warrants attached to convertible notes also increased, impacting additional paid-in capital.
• The company will file a Form 10-Q for the quarter ended September 30, 2024, as soon as practicable.
• The company states that these changes will not impact its cash position, cash flow, revenues, or liquidity.

Sentiment

Score: 3

Explanation: The announcement of a restatement and the identification of a material weakness in internal controls are negative signals, despite the company's claim that cash flow and liquidity will not be affected.

Positives

• The company is taking corrective action by restating the financial statements.
• The company states that the restatement will not impact its cash position, cash flow, revenues, or liquidity.

Negatives

• The company identified material misstatements in previously issued financial statements.
• There was a material weakness in the company's internal control over financial reporting.
• Investors should no longer rely on the previously released financial statements for the affected periods.

Risks

• The restatement could lead to a loss of investor confidence.
• The material weakness in internal control over financial reporting could indicate further issues.
• The company's ability to file the Form 10-Q for the quarter ended September 30, 2024, 'as soon as practicable' is not guaranteed.

Future Outlook

The company will file a Form 10-Q for the quarter ended September 30, 2024, as soon as practicable.

Management Comments

• The company evaluated the materiality of these errors both qualitatively and quantitatively.
• The foregoing changes will not have any impact on the Company's cash position, cash flow, revenues or liquidity.

Industry Context

Restatements are generally viewed negatively by the market as they indicate potential issues with a company's accounting practices and internal controls. The impact on Marizyme will depend on the magnitude of the restatement and the market's perception of the company's ability to rectify the issues.

Comparison to Industry Standards

• It's difficult to compare Marizyme's situation directly to industry standards without knowing the specific details of the misstatements and the company's overall financial health.
• However, restatements are not uncommon, particularly among smaller companies with less robust internal controls.
• Companies like Valeant Pharmaceuticals (now Bausch Health) and WorldCom have faced significant repercussions from restatements due to accounting irregularities.
• The severity of the impact depends on the nature and extent of the errors, as well as the company's response and remediation efforts.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment due to the restatement.
• The company's reputation may be damaged.
• Creditors may reassess the company's creditworthiness.

Next Steps

• The company will restate its financial statements for the quarters ended March 31, 2024, and June 30, 2024.
• The company will file a Form 10-Q for the quarter ended September 30, 2024, as soon as practicable.

Key Dates